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Abstract 
In phase II/III trials, cutaneous side effects of pazopanib were reported in less than 20% of 
patients, with only 1–3% being grade 3/4. We present a case of a 66-year-old man with a 
previous history of left nephrectomy for a stage II clear cell renal carcinoma. Approximately 
18 months later, recurrent disease in the lungs, mediastinum, and left psoas and bulky ab-
dominal/pelvic nodal metastasis were documented. He was initially treated with pazopanib 
800 mg q.d. and 1 week after starting this therapy, the patient presented with palpable pur-
pura on his ankles. These lesions regressed within 2 weeks off pazopanib, but had recurred 4 
weeks after he resumed medication at 400 mg q.d. Biopsy of the lesions revealed leukocyto-
clastic vasculitis. Despite tumour response to therapy, pazopanib was discontinued with total 
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resolution of this skin toxicity within 2 weeks of his cutaneous toxicity. To the best of our 
knowledge, we report a rare yet significant cutaneous adverse reaction to pazopanib. 
 © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Several tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors 
(VEGFRs) have been established in the treatment of metastatic renal cell carcinoma (mRCC) 
[1]. Pazopanib hydrochloride (VOTRIENT; Novartis Europharm) is an oral, multitargeted 
anti-VEGFR-1, -2, and -3, platelet-derived growth factor receptor α and β, and stem cell fac-
tor receptor (c-KIT) [2]. Pazopanib is approved for the treatment of mRCC in the first-line 
setting following the results of two randomised phase III trials demonstrating superiority to 
placebo and proved to be noninferior to sunitinib with a more favorable safety profile and 
improved patient-reported quality of life domains [3, 4]. In these studies, cutaneous side 
effects of pazopanib were reported in less than 15–20% of patients. These side effects are 
usually mild with only 1–3% of grade 3 or 4 toxicities reported [2, 5]. The pathophysiology 
of skin changes is largely unknown and all cutaneous manifestations cannot be attributed to 
the same mechanism [6, 7]. Vasculitis, as a consequence of pazopanib treatment, has been 
rarely reported [8, 9]. Cutaneous leukocytoclastic vasculitis (CLCV) may be idiopathic or 
secondary to another disease, such as malignancy (including mRCC) or an adverse drug reac-
tion (ADR) to a drug [6]. To our knowledge, this is the first report of this cutaneous ADR to 
pazopanib and, therefore, oncology providers should be aware of this clinical association.  
Case Presentation 
A 66-year-old Caucasian man, ex-smoker (1 pack per day), underwent a left nephrecto-
my for a stage II (T2N0M0), clear cell, Fuhrman grade 2/4 RCC in June 2015. His past medi-
cal history included hypertension, dyslipidaemia, obstructive sleep apnoea and benign pros-
tatic hypertrophy, for which he is chronically medicated with irbesartan/hydrochloro-
thiazide, pitavastatin, and Serenoa repens (permixon). Family history was significant for gas-
tric cancer in his father at 63 years of age.  
Approximately 18 months after his renal surgery, the patient was admitted with pro-
gressive shortness of breath and fatigue for about 1 week. On general physical examination, 
he had an Eastern Cooperative Oncology Group performance status score of 1; his clinical 
evaluation was essentially normal, with the exception of inaudible breath sounds in the low-
er 2/3 of the left lung; no jaundice, rash, purpuric spots, or lymphadenopathy was noted. The 
laboratory findings are presented in Table 1 and were significant for anaemia grade 1 
(CTCAE v4.03) and elevated LDH. The transthoracic echocardiography documented an ex-
tensive left pleural effusion, conditioning the remaining imaging evaluation: electrocardio-
gram with low-voltage waveforms; chest CT presenting large left pleural effusion, several 
pleural nodules measuring more than 5 cm, associated left lower lobe atelectasis, and a sec-
ondary nodule in the apical segment of the right lower lobe; abdominal CT showing an ex-
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pansive heterogeneous mass adjacent and infiltrating the left psoas, measuring 6 × 3 cm, and 
bulky retroperitoneal para-aortic adenopathies, larger than 3 cm in diameter (Fig. 1). Video-
assisted thoracic surgery allowed pleural drainage of 3,000 mL of serohaematic fluid and 
pulmonary decortication with significant clinical improvement and confirmed the histologi-
cal confirmation of the metastatic clear cell RCC.  
Given the evidence of multi-organ recurrent disease, symptomatology, and his interme-
diate risk (IMDC risk score) [10], the patient was initially treated with pazopanib 800 mg q.d. 
After having completed 1 week on treatment, he developed palpable purpura lesions on his 
ankles, grade 3 (CTCAE v4.03) (Fig. 2). There was no haematological or biochemical abnor-
mality and urinalysis was normal (Table 1). Concomitant new medication was ruled out as a 
possible cause of vasculitis. The patient held pazopanib with significant improvement of his 
skin changes therapy and reintroduced 2 weeks after at 400 mg q.d. Approximately 4 weeks 
later, he again developed recurrent skin lesions with the same severity. At this time, a 
dermato-oncologist examined the patient and a skin biopsy was performed, which set the 
diagnosis of CLCV (Fig. 2). Autoantibodies were negative and rheumatoid factor and C3/C4 
levels were within normal limits (Table 1). Viral serological testing was negative. Doppler 
ultrasound arterial/venous mapping of the lower limbs showed moderate bilateral tibioper-
oneal obliteration disease. The pazopanib treatment was discontinued and he had complete 
resolution of the skin lesions within 2 weeks.  
Considering the absence of disease progression, the clinical improvement, and laborato-
rial response (LDH normalisation) to pazopanib (despite the short-term treatment), the 
option was to switch to sunitinib 50 mg q.d. on a 4-week on/2-week off schedule. Approxi-
mately 3 weeks later, he presented again with the same palpable purpura grade 3 on his 
ankles. Sunitinib was discontinued and he started on prednisone 30 mg q.d. with rapid reso-
lution of the vasculitic skin lesions. The present case was discussed with the Dermatology 
team and although it was felt that his skin toxicity was likely anti-VEGF related rather than 
pazopanib related, the decision was to resume sunitinib at a lower dose of 37.5 mg q.d. on a 
4-week on/2-week off schedule and to taper down prednisone to 5 mg q.d. The patient 
stayed at the lower dose of sunitinib and corticotherapy for 6 more months, without any skin 
toxicity or any other significant adverse events. Unfortunately, his restaging scans at 6 
months revealed progressive disease and sunitinib was discontinued (Fig. 3). The patient is 
currently on nivolumab 3 mg/kg q2w and expected for the first assessment scans at 12 
weeks.  
Discussion 
CLCV, cutaneous small-vessel vasculitis, hypersensitivity vasculitis or angiitis, are all 
used interchangeably for a type of skin-predominant vasculitis, which most commonly pre-
sents with palpable purpura or nonspecific lesions on the lower extremities. Histologically, 
CLCV is characterised by leukocytoclasis, which refers to a vascular damage caused by nu-
clear debris from infiltrating neutrophils (Fig. 2) [6].  
A clinically useful classification scheme for CLCV could be based on aetiology, differenti-
ating between primary (idiopathic) and secondary disease. Approximately 50% of cases are 
idiopathic, while infection (15–20%), inflammatory diseases (15–20%), drugs (10–15%), 
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and malignancy (<5%) are the predominant secondary causes of CLCV. This disease is pre-
sumed to be associated with an aberrant hypersensitivity reaction to an exogenous antigen 
such as a drug, an infectious agent, or an endogenous antigen, such as vasculitis associated 
with neoplasms, connective tissue diseases, retroperitoneal fibrosis, ulcerative colitis, or 
congenital/acquired deficiencies of complement system [6].  
Vasculitis as a consequence of pazopanib treatment has been rarely documented. Based 
on US Food and Drug Administration data, 12,301 patients reported to have side effects 
when taking this drug. Among them were 6 patients (0.05%) with vasculitis, especially fe-
male (5/6), older than 60 years (6/6), and having taken pazopanib for less than 1 month 
(6/6), also with medication containing calcium (1/6) and paracetamol (1/6) [8]. On the oth-
er hand, the 6,442 patients included in the European Medicines Agency data reported side 
effects, of which 4 patients had vasculitis (0.06%) [9]. Although these updated review analy-
sis must be interpreted with caution given the rarity of this phenomenon, there is incom-
plete information about each case and none of them has yet been described in the literature. 
According to a PubMed and Ovid search of articles indexed to MEDLINE using the terms 
“Pazopanib” and “Vasculitis,” 12 articles were found, but none reported a treatment-induced 
vasculitis.  
Several studies have found that cutaneous ADR is very common with TKIs (more than 
10%). In the PharmacoVigilance Database, the most frequently reported serious cutaneous 
reactions were rash and hand-foot syndrome, more commonly associated with sorafenib 
(40%), erlotinib (25.2%), imatinib (13%), sunitinib (13%), dasatinib (3.5%), lapatinib 
(3.5%), and nilotinib (0.9%); no serious cutaneous ADR was reported with gefitinib or pazo-
panib [5]. Indeed, in the literature, there are a few cases of CLCV associated with TKIs. Six 
cases have been described with erlotinib, 2 cases with imatinib, sorafenib, and sunitinib, 1 
secondary to gefitinib, and another one possibly related with dasatinib [5, 6].  
In our case, we consider the CLCV an ADR, since all other possible causes have been ex-
cluded. Despite the fact that CLCV could be related with the chronic medication performed in 
the outpatient, the cause-and-effect relationship with TKIs, and mainly with pazopanib, was 
demonstrated. Clinical and laboratory workout revealed no association of vasculitis with an 
infection or an underlying chronic disease. The CLCV could be also a sign of a rare para-
neoplastic syndrome associated with RCC. However, CLCV was not present at the initial di-
agnosis or relapse of RCC, developed while on pazopanib with tumour regression, and im-
proved with dose reduction and drug discontinuation.  
The reappearance of the skin lesions with sunitinib suggested a therapeutic class effect. 
The main hypothesis for the TKI-induced CLCV is the inhibition of the VEGFR pathway ex-
pressed in the cells of the immune system, including dendritic cells, T-regulatory cells, and 
myeloid-derived suppressor cells. At this level, the TKI molecules could enhance the anti-
tumour role of these immune actors with an immunomodulatory effect [6, 11].  
The management of CLCV requires treating the underlying cause, discontinuation of 
suspected medications, and considering topical/systemic treatment. One of the possible 
criticisms of our therapeutic approach may be related to the early cessation of pazopanib 
without considering a period of low-dose corticosteroid therapy, as was eventually done 
with sunitinib [6]. Another issue that might have been considered for our patient after CLCV 
control with corticosteroid maintenance could be related to the increased dose of sunitinib 
to 62.5 mg, given the induction of the CYP3A4 enzyme by prednisone, which results in a fast-
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er catabolism of the TKI [6]. Unfortunately, the patient had disease progression, so it was 
decided to start nivolumab 3 mg/kg q2w. At this time, based on the immunosuppressive role 
of corticosteroids and the hypothetical interference with the immunotherapy efficacy, the 
duration and optimal dose of steroids is unclear. However, the recent history of CLCV and 
the associated risk of vasculitis with immunotherapy, including immune checkpoint inhibi-
tors, has led us to choosing to maintain a low dose of prednisone [12–14].  
Herein, we report a case of a patient with advanced RCC who developed a significant an-
ti-VEGF-related CLCV. Interestingly, this skin toxicity was ultimately managed with dose 
reduction of the TKI and a low dose of steroids, allowing him to continue therapy until pro-
gressive disease. The rarity of this event leads to a lack of data regarding its management. 
The interdisciplinary approach is always encouraged, as it may facilitate the diagnosis and 
allow the initiation of the proper treatment faster. Analysis of spontaneous reports is the 
sole method to recognise the early signs of new drug reactions, like the one that we reported.  
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Fig. 1. Chest CT coronal view (upper left image) showing the left pleural effusion, several pleural nodules 
measuring more than 5 cm, and associated left lower lobe atelectasis. Chest CT axial view (upper right 
image) showing a secondary nodule in the apical segment of the right lower lobe. Abdominal CT axial 
views showing an expansive heterogeneous mass adjacent and infiltrating the left psoas, measuring 6 ×  
3 cm (lower left image) and bulky retroperitoneal para-aortic adenopathies, larger than 3 cm in diameter 
(lower right image).  
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Fig. 2. Scattered purpuric plaques on the left ankle surrounded by cicatrisation areas, reflecting a few 
weeks of evolution (left image). Histological examination revealed superficial capillaries with necrotic 
vessel walls infiltrated with polymorphonuclear leukocytes (right image, HE staining, magnification ×400).  
 
 
 
Fig. 3. Chest CT coronal view (left image) showing size reduction of the pleural nodules and only slight 
residual left pleural effusion remaining in the costophrenic angle. Abdominal CT axial view (right image) 
clearly showing the infiltrative retracting tumour lesion adjacent to the left psoas and invading the de-
scending colon. It is also depicted enlargement of the bulky retroperitoneal para-aortic adenopathies. 
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Table 1. Laboratory examinations 
   
   
 Value Normal range 
   
   
Haemoglobin, g/dL 10.3 0<13.0–17.0 
Erythrocytes, ×1012 cells/L 3.5 00<4.5–5.5 
Haematocrit, % 32.5 0<40.0–50.0 
Mean corpuscular volume, fL 91.8 0<80.0–97.0 
Mean cellular haemoglobin, pg 29.1 0<27.0–32.0 
Leukocyte count, ×109 cells/L 10.2 00<4.0–10.0 
Neutrophil count, ×109 cells/L 7.6 0<40.0–80.0 
Lymphocyte count, ×109 cells/L 1.3 0<20.0–40.0 
Platelet count, ×109 cells/L 352 0.<150–400 
Prothrombin time, s 12.8 0<10.3–12.8 
Activated partial thromboplastin, s 27.7 0<23.0–31.9 
Erythrocyte sedimentation rate, mm/h 36.0 00.<13 
C-reactive protein, mg/dL 14.5 00<1.0 
Glucose, mg/dL 90.0 00.<70–110 
Urea, mg/dL 29.0 00.<50 
Creatinine, mg/dL 1.1 00<0.7–1.3 
Albumin, g/L 3 00<3.4–5.0 
Total protein, g/L 8.3 00<5.7–8.2 
Total bilirubin, mg/dL 0.3 0<0.30–1.2 
Direct bilirubin, mg/dL 0.1 0<0.30 
γ-GT, U/L 72 00.<73 
Alkaline phosphatase, U/L 73 00.<45–129 
Alanine aminotransferase, IU/L 35 00.<10–49 
Aspartate aminotransferase, IU/L 25 00.<34 
Uric acid, mg/dL 6.4 00<3.7–9.2 
Lactate dehydrogenase, mg/dL 473 0.<120–246 
Creatine phosphokinase, mg/dL 73 00.<32–294 
Sodium, mmol/L 143.0 <132.0–146.0 
Potassium, mmol/L 3.5 00<3.5–5.5 
Chloride, mmol/L 100 0<99.0–109.0 
Calcium, mg/dL 8.4 00<4.6–5.3 
Phosphorus, mg/dL 3.1 00<2.4–5.1 
Urinalysis   
Protein Negative  
Haemoglobin Negative  
Blood cells Negative  
Antinuclear antibodies (ANA) Negative  
Anti-dsDNA Negative  
Antimitochondrial antibodies (AMA) Negative  
Anti-smooth muscle cell antibodies (ASMA) Negative  
Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) Negative  
Cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) Negative  
C3, mg/dL 145.60 00.<90–180 
C4, mg/dL 39.6 00.<10–40 
Rheumatoid factor, IU/mL 8.4 00.<14 
   
      
